Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUVEN LIFE SCIENCES Mar-19 |
ADCOCK INGRAM Jun-14 |
SUVEN LIFE SCIENCES/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 338 | 372 | - | |
Low | Rs | 169 | 268 | - | |
Sales per share (Unadj.) | Rs | 52.1 | 110.6 | - | |
Earnings per share (Unadj.) | Rs | 6.8 | -27.9 | - | |
Cash flow per share (Unadj.) | Rs | 8.6 | -23.1 | - | |
Dividends per share (Unadj.) | Rs | 1.50 | 0 | - | |
Dividend yield (eoy) | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 65.3 | 86.8 | - | |
Shares outstanding (eoy) | m | 127.28 | 168.78 | - | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.9 | 2.9 | 168.1% | |
Avg P/E ratio | x | 37.1 | -11.5 | -323.3% | |
P/CF ratio (eoy) | x | 29.6 | -13.9 | -213.5% | |
Price / Book Value ratio | x | 3.9 | 3.7 | 105.3% | |
Dividend payout | % | 22.0 | 0 | - | |
Avg Mkt Cap | Rs m | 32,272 | 54,029 | 59.7% | |
No. of employees | `000 | 1.1 | 4.3 | 25.2% | |
Total wages/salary | Rs m | 661 | 3,391 | 19.5% | |
Avg. sales/employee | Rs Th | 6,132.2 | 4,349.7 | 141.0% | |
Avg. wages/employee | Rs Th | 611.1 | 789.9 | 77.4% | |
Avg. net profit/employee | Rs Th | 803.5 | -1,096.0 | -73.3% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 6,635 | 18,673 | 35.5% | |
Other income | Rs m | 242 | 131 | 185.3% | |
Total revenues | Rs m | 6,877 | 18,804 | 36.6% | |
Gross profit | Rs m | 1,604 | -3,236 | -49.6% | |
Depreciation | Rs m | 221 | 806 | 27.5% | |
Interest | Rs m | 38 | 506 | 7.5% | |
Profit before tax | Rs m | 1,587 | -4,417 | -35.9% | |
Minority Interest | Rs m | 0 | -12 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 718 | 276 | 260.1% | |
Profit after tax | Rs m | 869 | -4,705 | -18.5% | |
Gross profit margin | % | 24.2 | -17.3 | -139.5% | |
Effective tax rate | % | 45.2 | -6.2 | -723.9% | |
Net profit margin | % | 13.1 | -25.2 | -52.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 6,232 | 13,677 | 45.6% | |
Current liabilities | Rs m | 1,490 | 7,695 | 19.4% | |
Net working cap to sales | % | 71.5 | 32.0 | 223.1% | |
Current ratio | x | 4.2 | 1.8 | 235.3% | |
Inventory Days | Days | 86 | 111 | 77.9% | |
Debtors Days | Days | 83 | 124 | 66.6% | |
Net fixed assets | Rs m | 4,043 | 7,972 | 50.7% | |
Share capital | Rs m | 127 | 87 | 146.8% | |
Net worth | Rs m | 8,310 | 14,656 | 56.7% | |
Long term debt | Rs m | 18 | 5,151 | 0.3% | |
Total assets | Rs m | 10,389 | 27,687 | 37.5% | |
Interest coverage | x | 43.1 | -7.7 | -557.5% | |
Debt to equity ratio | x | 0 | 0.4 | 0.6% | |
Sales to assets ratio | x | 0.6 | 0.7 | 94.7% | |
Return on assets | % | 8.7 | -15.2 | -57.6% | |
Return on equity | % | 10.5 | -32.1 | -32.6% | |
Return on capital | % | 19.5 | -19.8 | -98.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 356 | 1,594 | 22.3% | |
From Investments | Rs m | -279 | -489 | 56.9% | |
From Financial Activity | Rs m | -225 | 4,674 | -4.8% | |
Net Cashflow | Rs m | -148 | 5,779 | -2.6% |
Compare SUVEN LIFE SCIENCES With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare SUVEN LIFE SCIENCES With: GLENMARK PHARMA CIPLA DR. DATSONS LABS PROCTER & GAMBLE HEALTH LUPIN
Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.
For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.
For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
More Views on NewsIn this video, I'll tell you why I am recommending caution in the market at this time.
A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.
In this video I'll show you exactly how I go about picking stocks for trading.
100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.
More